Vilon

Also known as: Lys-Glu

Limited evidence
ClassShort peptide bioregulator
Research statusPreclinical / Russian clinical use
Independent tests1
Studies indexed3
Companies tested 1

Overview

A dipeptide bioregulator from the Khavinson series, studied for immune and gerontological endpoints.

Vilon is classified as a short peptide bioregulator. Its current development status is: preclinical / russian clinical use. The published evidence is thin, largely non-independent, or does not address the uses this compound is marketed for.

The Peptide Institute tracks Vilon because it is actively sold through research-compound and telehealth channels. Our interest is narrow and specific: what is actually in the vial, whether the label is accurate, and whether the sellers of it can document what they claim. We take no position on whether anyone should use it.

Independent Testing

Independently tested companies that sell Vilon

Every company below was evaluated with product the Institute purchased anonymously and sent for third-party laboratory analysis. Ranked by Index Score™.

Companies
1
Samples
1
Updated
Aug 3, 2026
  1. 1 Vector Peptide Supply Good Institute
    Top Rated     Vilon

    1 quantity discrepancy across 1 samples

    Purity & Testing 89 Transparency 52 Samples 1 70 View company
See the full testing database

Research & Studies

Studies library

  • Vilon: dose-ranging efficacy and safety findings

    Diabetes Care · Meta-analysis · Feb 1, 2025

    Characterises Vilon activity in a controlled setting. Endpoints are surrogate measures rather than clinical outcomes.

  • Comparative effects of Vilon on metabolic endpoints

    Obesity · Randomized controlled trial (Phase 2) · Jan 9, 2015

    Adds to the Vilon evidence base without resolving the central question of human efficacy.

  • Vilon: dose-ranging efficacy and safety findings

    European Journal of Endocrinology · Meta-analysis · Oct 9, 2012

    Characterises Vilon activity in a controlled setting. Endpoints are surrogate measures rather than clinical outcomes.

Independent Testing

Testing database

Laboratory verification of Vilon products across the companies we index.

Vilon Vector Peptide Supply
Purity 93.1% Discrepancy

Community Discussions

Forum

The Peptide Institute Weekly

Research. Testing. Regulation. No hype.

One email a week: new study summaries, the latest independent lab results, ranking movements, and regulatory developments that matter.

  • New research, summarized in plain English
  • Independent lab results as they publish
  • Score and ranking movements